Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000873273 | SCV001015233 | likely benign | not provided | 2024-01-01 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV002363281 | SCV002657291 | likely benign | Inborn genetic diseases | 2018-05-11 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
| Ce |
RCV000873273 | SCV004135796 | likely benign | not provided | 2023-01-01 | criteria provided, single submitter | clinical testing | CHD8: PP2, BP4, BS1 |
| Department of Pathology and Laboratory Medicine, |
RCV001355210 | SCV001550029 | likely pathogenic | Intellectual developmental disorder with autism and macrocephaly | no assertion criteria provided | clinical testing | The CHD8 p.L2114F variant was not identified in the literature. The variant was identified in dbSNP (ID: rs200566427) and ClinVar (classified as likely benign by Invitae). The variant was identified in control databases in 101 of 280646 chromosomes (1 homozygous) at a frequency of 0.0003599 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: Ashkenazi Jewish in 71 of 10354 chromosomes (freq: 0.006857), Other in 9 of 7136 chromosomes (freq: 0.001261), European (non-Finnish) in 21 of 128428 chromosomes (freq: 0.000164), but was not observed in the African, Latino, East Asian, European (Finnish), or South Asian populations. The p.-- residue is conserved in mammals and computational analyses (MUT Assesor, PolyPhen-2, SIFT, MutationTaster, Revel, FATHMM, MetaLR, DANN) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (Splice AI exome) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. |